Literature DB >> 7439247

Paracetamol pharmacokinetics in thyroid disease.

J C Forfar, A Pottage, A D Toft, W J Irvine, J A Clements, L F Prescott.   

Abstract

The absorption, distribution and elimination of oral paracetamol have been studied in patients before and after treatment of thyrotoxicosis (n = 7) and hypothyroidism (n = 4). Absorption was faster in patients with untreated thyrotoxicosis than when subsequently euthyroid. The peak paracetamol concentration, however, was lower in thyrotoxic patients due to an apparent increase in the total body clearance and a shorter plasma half-life. Both absorption and elimination rates were reduced in hypothyroid patients, but were not significantly different from the euthyroid results. When estimated using a two compartment model the total volume of distribution and the hybrid distribution rate constants were unrelated to thyroid status, but the apparent volume of the central compartment was significantly greater in the thyrotoxic group. These changes in drug disposition may contribute to differences in drug response seen in thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439247     DOI: 10.1007/bf00563010

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  DRUG TOXICITY AS A RESULT OF INTERFERENCE WITH PHYSIOLOGICAL CONTROL MECHANISMS.

Authors:  J R GILLETTE
Journal:  Ann N Y Acad Sci       Date:  1965-03-12       Impact factor: 5.691

2.  Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat.

Authors:  F B Thomas; J H Caldwell; N J Greenberger
Journal:  Ann Intern Med       Date:  1973-05       Impact factor: 25.391

3.  Riboflavin absorption in children with thyroid disorders.

Authors:  G Levy; M H MacGillivray; J A Procknal
Journal:  Pediatrics       Date:  1972-12       Impact factor: 7.124

4.  Effect of hyperthyroidism and hypothyroidism on the metabolism of testosterone and androstenedione in man.

Authors:  G G Gordon; A L Southren; S Tochimoto; J J Rand; J Olivo
Journal:  J Clin Endocrinol Metab       Date:  1969-02       Impact factor: 5.958

Review 5.  Drugs, diseases and altered gastric emptying.

Authors:  W S Nimmo
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  High performance liquid chromatographic estimation of paracetamol metabolites in plasma.

Authors:  P I Adriaenssens; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

7.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.

Authors:  M D Rawlins; D B Henderson; A R Hijab
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

8.  Paracetamol metabolism in chronic liver disease.

Authors:  J A Forrest; P Adriaenssens; N D Finlayson; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

Review 9.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Simple solid-phase radioimmunoassays for total tri-iodothyronine and thyroxine in serum, and their clinical evaluation.

Authors:  J Seth; A D Toft; W J Irvine
Journal:  Clin Chim Acta       Date:  1976-05-03       Impact factor: 3.786

View more
  12 in total

1.  Interaction of metoprolol with lorazepam and bromazepam.

Authors:  A K Scott; G A Cameron; G M Hawksworth
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

3.  Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.

Authors:  B Hallengren; O R Nilsson; B E Karlberg; A Melander; L Tegler; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

Authors:  J Sonne; S Boesgaard; H E Poulsen; S Loft; J M Hansen; M Døssing; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

6.  Effects of posture and sleep on the pharmacokinetics of paracetamol (acetaminophen) and its metabolites.

Authors:  R H Rumble; M S Roberts; M J Denton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 8.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

9.  Left ventricular function in hypothyroidism. Responses to exercise and beta adrenoceptor blockade.

Authors:  J C Forfar; A L Muir; A D Toft
Journal:  Br Heart J       Date:  1982-09

Review 10.  Clinical pharmacokinetics of paracetamol.

Authors:  J A Forrest; J A Clements; L F Prescott
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.